- Policy
- COVID-19 vaccination to start in February
- by Lee, Jeong-Hwan Jan 20, 2021 06:01am
- “COVID-19 vaccination begins at the end of February and early March, and will form herd immunity in November at the latest. If side effects occur only after the vaccination, the government will be fully responsible. I am urged to inoculate, and if the national anxiety increases and the need to take an initiative, as the president, I will not
- Policy
- NMO drugs ready for Korean market release within this year
- by Lee, Tak-Sun Jan 19, 2021 06:02am
- A group of rare disease neuromyelitis optica (NMO) treatments are preparing for the South Korean market. NMO is a chronic disease with a no specific treatment. Recently, however, a number of treatments for the disease have passed the U.S. Food and Drug Administration (FDA) and they are now readying for the South Korean health authority’
- Company
- Mavenclad can be prescribed at general hospitals
- by Eo, Yun-Ho Jan 19, 2021 06:02am
- New multiple sclerosis drug Mavenclad can be prescribed in general hospitals According to related industries, highly active recurrent multiple sclerosis treatment Mavenclad (Cladribine) by Merck has now passed the drug commitee (DC) of SMC, AMC, Shinchon Severance Hospital, and NCC. Mavenclad is the first short-term oral treatment that
- Company
- Big Pharmas busy reaching out for KRAS targeted therapy
- by Kim, Jin-Gu Jan 18, 2021 06:14am
- Global pharmaceutical giants are eager to develop targeted therapy for ‘Kirsten rat sarcoma viral oncogene homolog (KRAS)’ mutation, initially considered as an impenetrable technology for last four decades. Apparently, KRAS mutation is found in about one out of four cancer types. Specifically, the mutation is frequently found in canc
- Policy
- 68% to “wait and see” before COVID-19 vaccination
- by Jan 18, 2021 06:14am
- Apparently, six out of 10 people in South Korea are intending to ‘get inoculated after confirming the outcome’ of the COVID-19 vaccine. Only 28.6 percent answered they would ‘get inoculated as soon as possible.’ As requested by a public survey research firm KSTAT Research, Professor You Myung Soon at Seoul National University Grad
- Policy
- Celltrion announced results of external clinical trials
- by Lee, Tak-Sun Jan 18, 2021 06:13am
- The MFDS will hold a verification advisory group meeting on the 17th to evaluate the appropriateness of the clinical trial results for COVID-19 treatment Rekirona developed by Celltrion. And it plans to announce the results on the 18th. After the verification advisory group meeting, the Central Pharmaceutical Affairs Review Committee and t
- Company
- Celltrion's COVID-19 antibody tx reduces progression by 54%
- by An, Kyung-Jin Jan 18, 2021 06:13am
- The result of Phase II clinical trial of Rekirona (Regdanvimab), COVID-19 antibody treatment developed by Celltrion, has been revealed for the first time. It is evaluated that it is useful to efficiently manage medical resources while reducing the incidence of severe patients requiring inpatient treatment by more than half and reducing the re
- Policy
- Will COVID-19 vaccine by SK be released first?
- by Lee, Tak-Sun Jan 15, 2021 06:11am
- Among AstraZeneca's COVID-19 vaccines that have been applied for approval from the MFDS, it is highly likely that the vaccine that SK Bioscience is consigning and producing will be distributed for the first time in Korea. Recently, the MFDS has reported that item approval and lot release can be reviewed in duplicate to speed up the market
- Company
- LG Chem in full throttle seeking anti-obesity and NASH drug
- by An, Kyung-Jin Jan 15, 2021 06:10am
- LG Chem showcased its key new drug pipelines targeting obesity and non-alcoholic steatohepatitis (NASH) at a global event. The South Korean company plans to make the chimeric antigen receptor T (CAR-T) cell therapy and stem cell therapy development into their future growth engine. On Jan. 13, LG Chem announced it would participate in the
- Policy
- Tamiflu for oral suspension has withdrawn
- by Lee, Tak-Sun Jan 15, 2021 06:10am
- Roche's original influenza treatment Tamiflu for oral suspension is withdrawn from the domestic market due to the expiration of the product license. Generics for Tamiflu for oral suspension occupied in advance. As of the 13th, the MFDS withdrew Tamiflu for oral suspension 6mg/ml (Oseltamivir) from Roche Korea due to the expiration of the p
